Company Analysis
Sign in

C4 Therapeutics, Inc. (CCCC)

Nasdaq: CCCC · Biological Products, (No Diagnostic Substances) · Watertown, MA · filing with the SEC since 2016
Full chart Alerts Compare
Grade5.1
◀ Past 5.4● Present 5.1▶ Future 4.8
1 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

33 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to C4 Therapeutics, Inc.’s names, not what it holds today.

Patents granted
33
33 utility, 1976 to Dec 31, 2025
Granted in 2025
8
Against 8 in 2024 and 7 in 2023
Applications published
65
15 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Organic fine chemistry23
Pharmaceuticals7
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
C4 THERAPEUTICS, INC. its own name
US, as the owner printed on each patent
33 granted
61 published
C4 Therapeutics, Inc. its own name
named as the applicant on its applications, in US
0 granted
4 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Dec 2, 202512,486,290Isoindolinone and indazole compounds for the degradation of EGFRPharmaceuticalsC4 THERAPEUTICS, INC.
Dec 2, 202512,486,253Therapeutics for the degradation of mutant BRAFOrganic fine chemistryC4 THERAPEUTICS, INC.
Oct 28, 202512,454,521Targeted protein degradationOrganic fine chemistryC4 THERAPEUTICS, INC.
Oct 14, 202512,441,740N/O-linked degrons and degronimers for protein degradationOrganic fine chemistryC4 THERAPEUTICS, INC.
Sep 23, 202512,421,220Bicyclic-substituted glutarimide cereblon bindersOrganic fine chemistryC4 THERAPEUTICS, INC.
Jul 29, 202512,371,442Isoindolinone and indazole compounds for the degradation of EGFRPharmaceuticalsC4 THERAPEUTICS, INC.
Jul 22, 202512,365,681Dihydrobenzimidazolones for medical treatmentOrganic fine chemistryC4 THERAPEUTICS, INC.
Feb 18, 202512,227,504Spirocyclic compoundsOrganic fine chemistryC4 THERAPEUTICS, INC.
Dec 31, 202412,180,225N/O-linked degrons and degronimers for protein degradationOrganic fine chemistryC4 THERAPEUTICS, INC.
Dec 3, 202412,157,735Compounds for targeted degradation of BRD9Organic fine chemistryC4 THERAPEUTICS, INC.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Dec 18, 20252025/0382285BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERSOrganic fine chemistryC4 THERAPEUTICS, INC.
Dec 4, 20252025/0368631BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERSOrganic fine chemistryC4 THERAPEUTICS, INC.
Sep 18, 20252025/0289827MORPHIC FORMS OF A MUTANT BRAF DEGRADER AND METHODS OF MANUFACTURE THEREOFPharmaceuticalsC4 THERAPEUTICS, INC.
Sep 11, 20252025/0282780SPIROCYCLIC COMPOUNDSOrganic fine chemistryC4 THERAPEUTICS, INC.
Aug 28, 20252025/0270234ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFRPharmaceuticalsC4 THERAPEUTICS, INC. · patent 12,486,290 granted from it
Apr 24, 20252025/0127903SUBSTITUTED PIPERIDINE DEGRONIMERS FOR TARGET PROTEIN DEGRADATIONOrganic fine chemistryC4 THERAPEUTICS, INC.
Apr 17, 20252025/0122179BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERSOrganic fine chemistryC4 THERAPEUTICS, INC. · patent 12,421,220 granted from it
Apr 17, 20252025/0121070COMPOUNDS FOR THE TARGETED DEGRADATION OF SMARCA2Organic fine chemistryC4 THERAPEUTICS, INC.
Apr 17, 20252025/0121069HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATIONPharmaceuticalsC4 THERAPEUTICS, INC.
Apr 10, 20252025/0115580THERAPEUTICS FOR THE DEGRADATION OF MUTANT BRAFPharmaceuticalsC4 THERAPEUTICS, INC. · patent 12,486,253 granted from it
What it applied for, 2024 to 2025: Organic fine chemistry 16 · Pharmaceuticals 11.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton CCCC · research, not advice